Ignite Creation Date:
2025-12-24 @ 10:47 PM
Ignite Modification Date:
2026-01-05 @ 3:41 PM
Study NCT ID:
NCT00660569
Status:
COMPLETED
Last Update Posted:
2010-12-01
First Post:
2008-04-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Utilization Patterns of Pulmicort in Real Life Practice
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001249', 'term': 'Asthma'}, {'id': 'D010342', 'term': 'Patient Acceptance of Health Care'}], 'ancestors': [{'id': 'D001982', 'term': 'Bronchial Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012130', 'term': 'Respiratory Hypersensitivity'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D000074822', 'term': 'Treatment Adherence and Compliance'}, {'id': 'D015438', 'term': 'Health Behavior'}, {'id': 'D001519', 'term': 'Behavior'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 260}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2010-11', 'completionDateStruct': {'date': '2009-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2010-11-30', 'studyFirstSubmitDate': '2008-04-15', 'studyFirstSubmitQcDate': '2008-04-15', 'lastUpdatePostDateStruct': {'date': '2010-12-01', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-04-17', 'type': 'ESTIMATED'}}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['asthma treatment', 'utilization', 'real life practice'], 'conditions': ['Asthma']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Population treated by General Practitioner, Pneumologists or Paediatricians', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion\n* Patients previously treated with Pulmicort CFC who have changed their treatment to Pulmicort HFA\n\nExclusion Criteria:\n\n* Disability that, from investigator point of view, prevent from complying the follow up schedule\n* To have participated in any clinical study in the past 6 months'}, 'identificationModule': {'nctId': 'NCT00660569', 'briefTitle': 'Utilization Patterns of Pulmicort in Real Life Practice', 'organization': {'class': 'INDUSTRY', 'fullName': 'AstraZeneca'}, 'officialTitle': 'Utilization Patterns of Pulmicort HFA in Real Life Practice', 'orgStudyIdInfo': {'id': 'NIS-RES-PUL-2007/1'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1', 'description': 'Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA'}]}, 'contactsLocationsModule': {'locations': [{'city': 'Barcelona', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Sabadell', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.54329, 'lon': 2.10942}}, {'city': 'Alcorcón', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 40.34582, 'lon': -3.82487}}, {'city': 'Leganés', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 40.32718, 'lon': -3.7635}}, {'city': 'Madrid', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'San Sebastián de los Reyes', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 40.55555, 'lon': -3.62733}}, {'city': 'Murcia', 'state': 'Murcia', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 37.98704, 'lon': -1.13004}}, {'city': 'Olivares', 'state': 'Sevilla', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 37.41802, 'lon': -6.15603}}, {'city': 'Toledo', 'state': 'Toledo', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 39.8581, 'lon': -4.02263}}, {'city': 'Fuentes de Ebro', 'state': 'Zaragoza', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.5125, 'lon': -0.63159}}], 'overallOfficials': [{'name': 'Javier Nuevo Rivero', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AstraZeneca MC SpainEpidemiologyValue Demonstration Unit'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AstraZeneca', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Mónica Tafalla/Medical Science Director', 'oldOrganization': 'AstraZeneca'}}}}